Carline Robert, MD | Authors

HyVee

625 W 40 Hwy

Lees Summit

64082

Articles

Cutaneous Side Effects of Multikinase Inhibitors Used in Renal Cell Cancer

May 01, 2007

Paralleling the increasing use of multikinase inhibitors in the field of cancer therapy, patients and clinicians are confronted with frequently occurring cutaneous side effects associated with the use of these new drugs. Two such targeted agents, sunitinib (Sutent) and sorafenib (Nexavar), were recently approved by the US Food and Drug Administration to treat patients with metastatic renal cell cancer (RCC).